FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system - FDA Press Releases

FDA approves Soliris (eculizumab) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

from FDA Press Releases RSS Feed https://ift.tt/2xiq0xO
via IFTTT